Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing a reference and esoteric anatomic pathology testing service with national ambitions. Within days of
Tag: cytology laboratory
Last Friday, the acquisition of Southern Diagnostic Laboratories, Inc., of Birmingham, Alabama, was announced by Solstas Lab Partners of Greensboro, North Carolina. Steve Boyd, who is the Founder and CEO of Southern Diagnostics, will become a Senior Vice President at Solstas. Revenues at privately-held Southern Diagnostics were reported to be $18.9 million in 2009.
CEO SUMMARY: Most laboratory professionals don’t know it yet, but significant changes occurred to the entire lab industry last week. After Quest Diagnostics Incorporated acknowledged that it was retesting tens of thousands of patients because 7% of the Vitamin D results it reported during an 18-month period were inaccurate, a blitz of newspaper headlines and
CEO SUMMARY: Like many labs today, the gynecologic cytology laboratory at the University of Iowa Hospitals and Clinics had a pre- and post-analytical work flow with many complex steps. This work flow—heavily influenced by a legacy of previous information systems—was inefficient, contained unnecessary redundancies, and lacked systematic measures for preventing errors. That all changed when
SOMEONE ALWAYS HAS TO BE FIRST to adopt new technology. In the case of automated cytology, it will be SmithKline Beecham Clinical Laboratories (SBCL).
SBCL and NeoPath, Inc. announced a four-year national agreement between the two companies on October 9 which will eventually allow SBCL to process 100% of its annual Pap smear volume using NeoPath’s
CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs. AutoCyte’s product positioning will be very different than its competitors: NeoPath,
CEO SUMMARY: Cytyc, NeoPath and Neuromedical each tapped the public capital markets during the past 18 months. Now investors expect to see earnings growth and dividends as soon as possible. Clinical laboratories should expect intensified sales and marketing efforts from these three companies as they strive to increase sales.
Probably the most ubiquitous sales representatives visiting
CEO SUMMARY: California’s financially destructive capitation rates plunged two more laboratories into bankruptcy. Unilab’s actions indicate that even the largest laboratory company in the state can no longer survive without reimbursement relief. The question remains as to whether managed care plans will agree to pay more for laboratory testing.
INDICATIONS ARE THAT CAPITATED RATES for laboratory